aaiPharma Inc. Wilmington, North Carolina
aaiPharma Inc. is a science-based, specialty pharmaceutical company with more than 22 years of drug development experience. Focusing on targeted therapeutic areas, the Company markets a growing portfolio of established branded products and applies innovative technologies to increase the commercial potential of these products. At the same time, aaiPharma's research and development organization is developing an impressive pipeline of products to position the Company for near-term and long-term growth in its targeted therapeutic areas. In addition to developing and marketing its own line of proprietary pharmaceutical products, aaiPharma continues to be a world leader in providing contract pharmaceutical development services through its AAI International division. NOTE: Merger with CIMA Labs announced 8/05/2003, terminated 11/03/2003.
Abbott Laboratories, Inc. Abbott Park, Ilinois
For more than a century, Abbott Laboratories has been working to advance health care for people around the world. Founded by a young Chicago physician, Dr. Wallace Calvin Abbott, in 1888, Abbott Laboratories has evolved into a diversified health care company that discovers, develops, manufactures and markets innovative products and services that span the continuum of care – from prevention and diagnosis to treatment and cure. Headquartered in north suburban Chicago, Abbott helps people around the world in the more than 130 countries.
Building leadership and combining strengths in the areas of pharmaceuticals, nutritionals, hospital products and diagnostics has enabled Abbott to provide total, integrated solutions across the health care spectrum for some of the world’s most prevalent medical conditions, including AIDS, cancer and diabetes. We focus on advancing medical science and the practice of health care with expertise in the therapeutic areas of diabetes, pain management, respiratory infections, HIV/AIDS, men and women’s health, pediatrics and animal health.
Abgenix, Inc. Fremont, California
We are a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions, including cancer, inflammatory and autoimmune disorders, transplant-related diseases, cardiovascular disease and infectious diseases. We have proprietary technologies that facilitate rapid generation of highly specific, antibody therapeutic product candidates that contain fully human protein sequences and that bind to disease targets appropriate for antibody therapy. We refer to these candidates as fully human antibody therapeutic candidates. We developed our XenoMouse® technology, a technology using genetically modified mice to generate fully human antibodies. We also own a technology that enables the rapid identification of antibodies with desired function and characteristics, referred to as SLAM™ technology. In our XenoMax™ technology, we use SLAM technology to select and isolate antibodies with particular function and characteristics from antibody-producing cells generated by XenoMouse animals. We believe XenoMax technology enhances our capabilities in product development and flexibility in manufacturing. We intend to use our technologies to build a large and diversified product portfolio that we expect to develop and commercialize through licensing arrangements with pharmaceutical companies and others, through joint development and through internal product development programs. We have entered into a variety of contractual arrangements with multiple pharmaceutical, biotechnology and genomics companies involving our XenoMouse technology. Two of our customers, Pfizer and Amgen, have initiated clinical trials with fully human antibodies generated from XenoMouse animals. In addition, as of March 31, 2002, we had four proprietary antibody product candidates in clinical trials, one of which we had agreed to co-develop and commercialize with Immunex Corporation and one of which we had agreed to co-develop and commercialize with SangStat Medical Corporation.
ActivBiotics, Inc. 128 Spring Street Lexington, Massachusetts 02421
ActivBiotics is a clinical stage company committed to significantly improving the treatment of acute infections and chronic diseases caused or exacerbated by microbial pathogens. The Company's lead compound, rifalazil, is being investigated in a Phase II trial for sexually transmitted diseases and is preparing to enter Phase II trials in other indications. In addition, the Company has a highly productive program to develop proprietary new chemical entities. The program is producing both narrow and broad spectrum compounds with unprecedented potency and concomitantly improved resistance profile. Email: info@activbiotics.com
Adolor Corporation Exton, Pennsylvania
Adolor Corporation is a late-stage biopharmaceutical company committed to the development and commercialization of novel products to relieve pain and reduce the side effects of currently marketed narcotics. Adolor’s lead product candidate, alvimopan™, is a first-in-class compound that is in Phase 3 clinical trials for two indications: post-operative ileus and opioid bowel dysfunction, both of which represent large unmet medical needs. The company is also developing a series of next-generation peripherally acting kappa opioid compounds for the treatment of pain associated with acute and chronic inflammatory diseases. These compounds have the potential to revolutionize existing pain management markets because of their ability to relieve pain as effectively as morphine and other opioid narcotics, without the severe adverse side effects and addiction potential associated with opioid narcotics. Adolor’s strategy is to combine near-term commercialization opportunities with a longer-term approach to develop novel opioid analgesics based upon a new molecular understanding of the function of opioid receptors. Adolor combines the expertise of world leaders in molecular biology, pharmacology and chemistry with experienced pharmaceutical and biotechnology management. As Adolor moves towards commercialization, the company continues to add key personnel with clinical development, regulatory and commercialization expertise. The Company’s strategic goal is to establish a pharmaceutical franchise in pain management.
Aerogen, Inc. Mountain View, California
Aerogen, an emerging specialty pharmaceutical company, is developing inhaler and nebulizer products, based on its proprietary aerosol generator technology, for the treatment of respiratory disorders in the home and hospital markets. Aerogen is also applying its technology to develop products in collaboration with pharmaceutical and biotechnology companies for the treatment of respiratory and other disorders. Aerogen now markets two Aeroneb nebulizer systems, one optimized for professional use in the hospital and the other for home use.
Aeterna Laboratories, Inc. 1405 Parc-Technologique Blvd. Quebec City, Quebec, CANADA G1P 4P5
AEterna Laboratories has an extensive portfolio of marketed and development-stage biopharmaceutical products focused in oncology and endocrinology. Its lead oncology compound is Neovastat®, a proprietary angiogenesis inhibitor with multiple mechanisms of action in a Phase III clinical trial for renal cell carcinoma (data available by year-end 2003) and in a Phase III trial for non-small cell lung cancer. Cetrotide®, its lead compound in endocrinology is sold in the U.S. and Europe to the "in vitro" fertilization market, and is in clinical testing for endometriosis, uterus myoma and enlarged prostate (BPH). A further seven clinical programs are underway with various compounds. Email: paul.burroughs@aeterna.com
Alcon Laboratories, Inc. Fort Worth, Texas
From its inception more than 50 years ago, Alcon has committed itself to the discovery and development of specialty pharmaceuticals that address both chronic and acute diseases of the eye. We are committed not just to the treatment of a single eye disease or disorder, such as gluacoma, but to all of the major diseases of the eye including infection, inflammation, allergy, dry eye and macular degeneration. Over the years, Alcon has become the global leader in specialty ophthalmic pharmaceuticals, with the broadest array of products of any company in the industry around the world. With a large sales force covering ophthalmologists, optometrists, pediatricians, allergists and primary care physicians, we are uniquely positioned in the industry to market effectively to all physicians and eye care professionals who might prescribe our eye medications.
Alexion Pharmaceuticals Cheshire, Connecticut
Alexion's strategy is to build on its strong scientific and product development base to develop novel antibody therapeutics targeting the treatment of patients with a wide array of severe disease states, including cardiovascular and autoimmune disorders, inflammation and cancer. Alexion is dedicated to developing effective and safe treatments for human diseases for which treatment options are either non-existent or inadequate.
Alfacell Corporation 225 Belleville Avenue Bloomfield, New Jersey 07003
Alfacell is a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonucleases (RNases). Our mission is to develop new therapeutics from our novel ribonuclease technology platform for the treatment of cancer, infectious diseases and other life threatening conditions, thus offering new horizons of hope for patients and physicians.
Email: info@alfacell.com
Allergan, Inc. Irvine, California
Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people's lives.
Allos Therapeutics, Inc. 11080 CirclePoint Road Suite 200 Westminster, Colorado 80020
Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and non-Hodgkin's lymphoma. Email: mgreer@allos.com
Alnylam Pharmaceuticals, Inc. 790 Memorial Drive, Suite 202 Cambridge, Massachusetts 02139
Alnylam is the leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a Revolution in Biology for Human Health(TM). Growing from its foundation as the world's first company focused on RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Ribopharma of Kulmbach, Germany. Over the last several years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi-based therapeutics. The company's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral, oncologic, metabolic, CNS and autoimmune diseases. The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders Email: rbean@alnylam.com
Alpha Therapeutic Corporation Los Angeles, California
Headquartered in Southern California, Alpha Therapeutic has offices and facilities throughout the United States. A subsidiary, Alpha Therapeutic Services, is a nationwide provider of home infusion products and services. In addition, the company has international affiliates in the United Kingdom, Germany, Spain, Italy, Thailand and Singapore.
Alpharma U.S. Pharmaceuticals Division Baltimore, Maryland
Marketing the broadest portfolio of specialty pharmaceuticals in the industry with over 150 products in both prescription and over-the-counter categories, Alpharma USPD is a major generic drug company with a substantial presence in consumer pharmaceuticals. Items are available in a wide range of product categories from respiratory and cough/cold to first aid and women's health. We are dedicated to providing our customers with the highest quality generic pharmaceuticals.
ALZA Corporation Mountain View, California
ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company with leading drug delivery technologies.
ALZA applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for many of the world's leading pharmaceutical companies as well as for its own portfolio. ALZA's strategy for building its commercial presence is to target specialty market opportunities, with a focus on urology, oncology and central nervous system (CNS) products. By developing, acquiring and marketing products in these areas, ALZA is establishing strong relationships with key physicians while providing a range of therapies to treat the individual needs of patients.
Amgen, Inc. Thousand Oaks, California
Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). At the time, Amgen's corporate mission was to be the world leader in discovering, developing and manufacturing cost-effective human therapeutics based on advances in cellular and molecular biology.
Currently, Amgen's Aspiration statement is to be the best human therapeutics company. We will live the Amgen values and use science and innovation to dramatically improve people's lives.
In-depth knowledge developed through the utilization of state-of-the-art cellular and molecular biology enables Amgen scientists to discover and develop both naturally occurring proteins and small molecules as potential human therapeutics.
Amylin Pharmaceuticals, Inc. 9373 Towne Centre Drive San Diego, California 92121
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. The Company’s two late-stage, first-in-class diabetes product candidates – SYMLIN® (pramlintide acetate) and exenatide (synthetic exendin-4) – are being developed to address the global epidemic of diabetes. Amylin has a strategic alliance with Eli Lilly and Company for the co-development and global commercialization of exenatide, and an extended release formulation, exenatide LAR. Building on its experience in the diabetes field, the Company is developing candidates for cardiovascular disease and obesity by utilizing its research experience with the metabolic properties common to all three conditions. Email: IR@amylin.com
Andrx Corporation Weston, Florida
Andrx Corporation is a specialty pharmaceutical company that applies its ten proprietary and patented oral controlled-release drug delivery technologies and formulation skills to the research and develoment of bioequivalent/generic (ANDA) and brand/proprietary (NDA) products. In its generic program, Andrx primarily develops bioequivalent versions of controlled-release brand products as well as difficult to replicate specialty, niche or immediate release brand name pharmaceuticals. In its brand program, Andrx applies its oral controlled-release technologies and formulation skills to develop improved versions of existing brand drugs, which will be marketed as new brand pharmaceuticals. Andrx also markets and distributes, primarily to independent pharmacies, pharmaceutical products manufactured by third parties.
Angiogene Pharmaceuticals Ltd. Oxfordshire, United Kingdom
Angiogene is a drug discovery company targeting diseases involving active angiogenesis. The company was originally formed in 1993 to exploit the expertise and intellectual property of the founding scientist, Dr. Graeme J. Dougherty, in the areas of gene therapy and vascular biology. Angiogene established its U.K. Office in 1996 and was registered in Scotland in 1997 as Angiogene Pharmaceuticals Ltd. The company's research is presently carried out at laboratories in the U.K. and in North America. In 1998 Angiogene secured its first major partnership with a large pharmaceutical company, licensing ANG453 to AstraZeneca. Renamed ZD6126, this compound is now in Phase I. Email: pdd@angiogene.co.uk
Arbor Pharmaceuticals, Inc. 4505 Falls of the Neuse Road, Suite 420 Raleigh, North Carolina 27609
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty
pharmaceutical company focused on the licensing, development, and
commercialization of products for pediatricians. Founded in 2006, Arbor
actively seeks out unique, patent-protected therapies proven to effectively
treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with
pharmaceutical development companies and established promotional partners in
the pharmaceutical industry to develop and market their products in order to
serve the needs of pediatricians throughout the US. Email: info@arborpharma.com
Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-Chome, Chuo-Ku Tokyo, Japan
Manufacturing, marketing and import/export of pharmaceuticals, quasi-drugs, foods and medical supplies and systems, and home care business, etc.
Astellas Pharma was formed from the merger of Fujisawa Pharmaceuticals and Yamanouchi Pharmaceuticals in April 2005.
AstraZeneca Corporation London, United Kingdom
AstraZeneca is one of the world's leading pharmaceutical companies. Backed by a strong research base and extensive manufacturing and commercial skills, we provide innovative, effective medicines that make a real difference for patients in important areas of healthcare. We aim to be the first with new ideas and innovative in all areas of our activity to create value for our customers, shareholders, employees and the communities in which we work.
AstraZeneca provides innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, central nervous system, gastrointestinal, infection, pain control and respiratory.
AtheroGenics, Inc. 8995 Westside Parkway Alpharetta, Georgia 30004
AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma.
AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clinical testing arena to ultimately establish the safety and efficacy of novel compounds that address serious unmet medical needs
AtheroGenics has assembled two synergistic technology platforms. Our proprietary v-protectantTM technology platform has been the foundation of our discovery research efforts, and is the basis of our first three compounds, currently in clinical development. Email: investor@atherogenics.com
AVANIR Pharmaceuticals San Diego, California
AVANIR Pharmaceuticals is a drug discovery and development company that has a commercialized FDA-approved product and a product in Phase III clinical trials. AVANIR is engaged in small molecule research to develop treatments for central nervous system disorders and inflammatory diseases. Through its subsidiary, Xenerex Biosciences, AVANIR also develops human monoclonal antibodies for therapeutic applications.
Aventis US Bridgewater, New Jersey
Aventis is now part of the sanofi-aventis Group.
The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines.
. Email: info@aventis-us.com
AVI BioPharma (AVI) One SW Columbia Suite 1105 Portland, Oregon 97258
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease and other cell proliferation disorders. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, AVICINE®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic and colorectal cancer. Email: avi@avibio.com
Axcan Pharma, Inc. Mont-Saint-Hilaire, Québec, Canada
Axcan is a leading specialty pharmaceutical company within the field of gastroenterology in North America and Europe. Axcan markets a broad line of pharmaceutical products used in the treatment of a variety of gastrointestinal diseases and disorders. In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on distribution of products and offers potential licensors the prospect of rapidly expanding the potential market for their products.
Axonyx Inc. New York, New York
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease, human memory disorders and prion-based illnesses such as Mad Cow Disease.
Barr Laboratories, Inc. 2 Quaker Road, PO Box 2900 Pomona, New York 10970
Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in developing, manufacturing and marketing generic and proprietary pharmaceuticals. Email: info@barrlabs.com
Barrier Therapeutics, Inc. 100 Overlook Center 2nd Floor Princeton, New Jersey 08540
Barrier Therapeutics, Inc. is a specialty pharmaceutical company focused on the development of novel dermatological therapeutics. The privately held company was formed to develop and market dermatological products based on intellectual property initially in-licensed from affiliates of Johnson & Johnson. Email: info@barriertherapeutics.com
Bausch & Lomb Rochester, New York
Bausch & Lomb is a global eye care company dedicated to helping consumers see, look, and feel better through innovative technology and design. Founded in 1853, the company has annual revenues of approximately $2 billion and employs approximately 12,000 people in 35 countries. Bausch & Lomb products are available in more than 100 countries around the world. Bausch & Lomb has three product lines: Vision Care, Surgical, and Pharmaceuticals.
Bayer Pharmaceutical Division Pittsburgh, Pennsylvania
Bayer Pharmaceuticals North America conducts business in three major areas of health care: prescription medications, biological products, and biotechnology. Bayer is also one of the world's largest producers of allergenic extracts, which are used by allergy professionals to desensitize patients suffering from various forms of allergy.
Bayhill Therapeutics Inc. 3430 W. Bayshore Road Suite 201 Palo Alto, California 94303
Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company has established a therapeutic platform of autoimmune modulators, in-licensed from Stanford University, that address the broad market of Th1 mediated autoimmune diseases. The Company's initial disease focus is multiple sclerosis, with its first product (BHT- 3009) entering Phase I/II studies in the first quarter of 2004. In addition, the Company has a strong portfolio of product programs focused around individual agents with demonstrated proof of concept as autoimmune modulators (AIM(TM)), as well as in the combination of these modulators in a proprietary manner, AIMTx(TM). Email: info@bayhilltherapeutics
Bentley Pharmaceuticals, Inc. Bentley Park Exeter, New Hampshire 03833
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of branded and generic pharmaceuticals in Spain for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar.
Email: invrel@bentleypharm.com
Berlex Laboratories, Inc. Montville, New Jersey
Berlex Laboratories, Inc., located in Wayne and Montville, NJ and Richmond, CA, is committed to bringing to the market beneficial preventive, diagnostic and therapeutic medicines in the strategic fields of Dermatology, Diagnostic Imaging, Female Healthcare, Therapeutics and Oncology. Driving our activities is a three-pronged emphasis on recognizing and addressing marketplace needs, improving the quality of life for patients and building strong relationships with the healthcare professionals who select and administer our pharmaceutical products.
Biogen Idec Inc. Cambridge, Massachusetts
In November 2003, Biogen Idec Inc.(NASDAQ: BIIB) was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing expertise, global infrastructure, and financial position. Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing.
Biogen Idec is dedicated to pursuing the creativity of science. The company’s products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and rheumatology.
nbsp; Merger of Biogen with IDEC Pharmaceuticals finalized 11/12/2003. Email: info@biogenidec.com
Biovail Pharmaceuticals, Inc. Morrisville, North Carolina
Biovail Pharmaceuticals Inc. markets Biovail and in-licensed products to physicians, pharmacists and hospitals across the United States. It was created in 2000, through the acquisition of DJ Pharma Inc., providing Biovail with an established network of U.S. sales professionals.
Since its inception, Biovail Pharmaceuticals Inc. has enhanced Biovail's presence in the U.S. marketplace through aggressive sales force expansion and the launch of new pharmaceutical brands.
Current products in its portfolio include Cedax®, Rondec®, Teveten®, Zovirax®, Cardizem®, Vasotec® and the Vaseretic® product line. This portfolio will be expanded through product licensing and acquisitions, as well as the addition of branded products developed by Biovail. Biovail Corporation (headquartered in Mississauga, Ontario, CANADA) is a full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacturing, sale and promotion of pharmaceutical products by utilizing advanced oral controlled-release and FlashDose® technologies.
Boehringer Ingelheim Corporation Ridgefield, Connecticut
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Boehringer Ingelheim corporation is a family-owned company. It is owned by a committee of private shareholders dedicated to the long term interests of the corporation´s stakeholders, including its customers, employees and the communities within which it operates. This distinctively independent structure makes it more possible to operate according to long term strategies rather than short term priorities. Best selling Prescription Medicines products: Combivent®, Flomax®, Atrovent®, Catapres®, Mobic®
Boston Life Sciences, Inc. Boston, Massachusetts
Boston Life Sciences, Inc. (BLSI) is a development stage biotechnology company engaged in the research and development of novel therapeutic and diagnostic solutions for central nervous system diseases (CNS) and cancer. BLSI's products in development include: ALTROPANE® and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. Email: IR@BostonLifeSciences.com
Bristol-Myers Squibb Company New York, New York
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. At Bristol-Myers Squibb, our mission is to extend and enhance human life by providing the highest-quality health care products and services. Our medicines are making a difference in the lives of millions of customers across the globe. And by living our mission and growing our company for well over a century, we are making a difference in the lives of our shareholders, employees and neighbors as well.
Cambridge Antibody Technology (CAT) Cambridge, United Kingdom
Cambridge Antibody Technology (CAT) is a world leading company in the discovery and development of human monoclonal antibody therapeutics.
Using its pioneering technologies, CAT has developed an impressive pipeline of novel human monoclonal antibody drugs. Six of these are currently at various stages of clinical trials, with a seventh (D2E7) having been submitted for regulatory review, following the completion of Phase III trials for the treatment of rheumatoid arthritis.
The Company's business is driven from a proprietary platform of phage display technologies. To maximise commercial opportunities, CAT has built an array of strategic collaborations with leading pharmaceutical and biotechnology companies worldwide.
Celgene Corporation Warren, New Jersey
Celgene Corporation is a specialty pharmaceutical Company engaged in the development and commercialization of human pharmaceuticals and agrochemicals. It employs two broad technology platforms: (i) small molecule immunotherapeutic compound development and (ii) biocatalytic chiral chemistry. The focus of the immunology program is the development of small molecule pharmaceuticals that selectively regulate Tumor Necrosis Factor alpha (TNF-alpha), a protein whose overproduction has been linked to many chronic inflammatory and immunological diseases. The company's lead compound is THALOMID® which was approved in 1998. THALOMID (thalidomide) which is currently indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID (thalidomide) is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID (thalidomide) is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Celgene has further applied its expertise in small molecule chemistry to develop novel and proprietary thalidomide analogues, called IMiDs™(Immunomodulatory Drugs) as well as a class of proprietary immunotherapeutic compounds called SelCIDs™ (Selective Cytokine Inhibitory Drugs) both of which are highly specific modulators of TNF-alpha.
Cellegy Pharmaceuticals South San Francisco, California
Cellegy Pharmaceuticals is a specialty biopharmaceutical company engaged in the development and commercialization of prescription drugs with primary focus in the areas of gastroenterology, sexual dysfunction and women's health care. Cellegy has developed expertise in the use of nitroglycerin ointment and nitric oxide donors to address a number of serious conditions. Cellegesic(TM) ointment for the treatment of anal fissures and hemorrhoids is currently awaiting FDA protocol approval of a confirmatory Phase III clinical trial to treat the severe pain associated with chronic anal fissures. The Company is also conducting clinical trials using Cellegesic to treat hemorrhoids. Other nitroglycerin based product candidates, in earlier clinical development, are targeting conditions including female sexual dysfunction, Raynaud's disease and prostate cancer.
Cellegy is also developing a second testosterone product, Tostrelle(TM) Gel for the treatment of female sexual dysfunction. Tostrelle is undergoing a phase II / III clinical trial in the United States and has generated significant interest from potential partners and the medical community.
CeMines, Inc. La Jolla, California
CeMines(TM) is a new-generation biotechnology company that applies the principles of gene regulation in development of early-stage diagnostics and targeted therapeutics for cancers and other diseases, based on the Company's patent-pending, proprietary biomarker technology known as CeMines Molecular FingerPrinting(TM).
CeMines™ has developed its breakthrough Molecular FingerPrinting™ blood test for the early-detection and optimized treatment of a variety of cancers and other immune diseases. Based on monitoring disease-specific molecular changes in gene regulatory machinery, CeMines™ believes that its minimally invasive diagnostic tests will provide accurate, early detection of most widespread cancers --including lung, breast, prostate and gastrointestinal - and can provide critical information in optimal treatment modalities.
Email: ir@cemines.com
Centocor, Inc. Malvern, Pennsylvania
Building on our leadership position in monoclonal antibody technology, Centocor creates, acquires and markets unique biopharmaceutical therapies. Our innovative products focus on the management of three major disease areas; cardiovascular, immunologic disorders and cancer. Centocor is proud to be part of the Johnson & Johnson family of companies.
Cephalon, Inc. West Chester, Pennsylvania
Cephalon seeks to discover, develop and market innovative products to treat neurological and sleep disorders, cancer, and pain. The company is committed to providing patients and the medical community with novel therapies to treat unmet medical conditions through its proprietary research programs and by acquiring promising products for clinical development and commercial sale. Our success is supported by a proven strategy of marketing high-growth, innovative products, building our worldwide marketing and distribution channels, and investing in research and development of unique compounds that may change the course of a disease. An international biopharmaceutical company headquartered in West Chester, Pennsylvania, with offices and manufacturing facilities in Salt Lake City, Utah. Cephalon's major European offices are located in Guildford, England, and at Laboratoire L. Lafon, in Maisons-Alfort, France. Founded in 1987 by Frank Baldino, Jr., Ph.D.
Co-founders: James Kauer, Ph.D. and Michael Lewis, Ph.D. Three growth products marketed in the United States and more than twenty products marketed globally. Revenue from product sales in 2001 was $226.1 million vs $91.6 million in 2000. Approximately 1,200 employees in the U.S. and Europe. Merger with CIMA LABS announced 11/03/03.
Chiron Corporation Emeryville, California
Chiron Corporation is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a difference in people's lives. The company has a strategic focus on cancer and infectious disease. Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop products from its platforms in proteins, small molecules and vaccines. The company commercializes its products through three business units: vaccines, blood testing, and biopharmaceuticals.
Chugai Pharma USA San Diego, California
Chugai Pharma USA, LLC discovers and develops therapeutic products that treat cardiovascular diseases, cancer, plus gastrointestinal and joint diseases. Our 72,000-sq. ft. facility in San Diego, California houses molecular biology, biochemistry, as well as high throughput screening, medicinal chemistry laboratories, and a large clinical development team. In line with our overall mission, Chugai Pharma USA is developing the infrastructure required to commercialize therapeutic drug products in the US. At CPUSA we strive to maintain a working environment that offers our employees ample opportunities and resources to realize their full potential and to advance within the organization.
CIMA Labs Inc. (CIMA) 10000 Valley View Road Eden Prairie, Minnesota 55344
CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, orally disintegrating drug delivery technologies, OraSolv® and DuraSolv®. Based on these technologies, an active drug ingredient, which the company frequently taste-masks, is formulated into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. CIMA's business involves a dual operating strategy. The company develops and manufactures orally disintegrating versions of drugs for pharmaceutical company partners for whom CIMA currently produces three branded prescription pharmaceuticals and three over-the-counter brands. CIMA is also developing proprietary products utilizing its orally disintegrating technologies, as well as its new OraVescent® enhanced absorption, transmucosal drug delivery technology. NOTE: Merger with aaiPharma originally announced 8/05/2003, was terminated 11/03/2003. Merger with Cephalon, Inc. announced 11/03/03. Email: webmaster@cimalabs.com
Confluent Surgical, Inc. Waltham, Massachusetts
Confluent is a private medical device company founded in August 1998, that is pioneering the development of In-situ-polymerized Biomaterials. These materials have almost universal applications across minimally invasive surgery, because they allow the safe, simple, and rapid, formation of customized implants at the site of disease. This process can take place rapidly when two aqueous solutions of molecularly designed synthetic polymers mix together. Confluent's vision is to address unmet needs in surgery and interventional procedures using its technology platform of in situ polymerization.
Connetics Corporation Palo Alto, California
Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05% and Luxiq(R) (betamethasone valerate) Foam, 0.12%. The Company also is developing Extina(TM), a foam formulation of the antifungal drug ketoconazole, and Actiza(TM), a foam formulation of clindamycin for treating acne. Connetics also recently in-licensed Velac(R) gel, a combination acne therapy. These formulations aim to improve the management of dermatological diseases, provide significant product differentiation, and extend product life cycles.
Cook Surgical Bloomington, Indiana
Cook Surgical markets medical biomaterials from acellular natural tissues through its tissue engineered products group. In addition, the company's growing team of medical device engineering and development specialists works with leading researchers at hospitals and university medical centers around the world to develop, test and perfect important new diagnostic and interventional medical products.
Corautus Genetics 6555 Nancy Ridge Drive San Diego, California 92121
Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development of innovative gene therapy products for the treatment of cardiovascular disease. Corautus Genetics was formed by the merger of Vascular Genetics Inc. with GenStar Therapeutics Corporation to capitalize on the complementary strengths of these companies to accelerate the development of a later stage product for cardiovascular disease. Corautus Genetics' core technology is based upon gene therapy for "therapeutic angiogenesis." In this approach, the injection of genes for vascular growth factors stimulate the formation of new blood vessels to help compensate for reduced blood flow due to advanced cardiovascular disease. The focus of the company's efforts will be the clinical development of gene therapy products using a vascular growth factor gene (Vascular Endothelial Growth Factor 2 or "VEGF-2") for the treatment of severe cardiovascular disease.
Email: info@corautus.com
Corixa Corporation Seattle, Washington
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune disease, cancer and infectious disease by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, BEXXAR®, a monoclonal antibody conjugated to a radioisotope.
Corus Pharma Inc. 2025 1st Avenue Ste 800 Seattle, Washington 98121
Corus Pharma seeks to develop drugs to treat unmet needs in the infectious diseases and respiratory areas. The company's core competencies reside in the identification of drug candidates, rapid clinical development and FDA approval of its products. Target development candidates will be identified through a combination of internal ideas, academic research and a search of projects in other organizations. Email: info@coruspharma.com
Corvas International, Inc. San Diego, California
Corvas International, Inc. is a biopharmaceutical company focused on the development of new biotherapeutics that address large medical markets, including cancer and cardiovascular disease. rNAPc2, Corvas' cardiovascular drug candidate currently in Phase II clinical trials, is a novel anticoagulant intended for the treatment of people affected by acute coronary syndromes, which include unstable angina and non-ST-segment elevation myocardial infarction. Corvas' cancer research programs are focused on the development of new biotherapies, including monoclonal antibodies and synthetic prodrugs, that target serine proteases associated with the growth and spread of cancerous tumors. Note: Merger with Dendreon Corporation approved by Corvas shareholders on 7/28/2003.
Email: ir@corvas.com
Cubist Pharmaceuticals, Inc. Lexington, Massachusetts
Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel pharmaceuticals to combat serious and life-threatening infections. Cubist is evaluating the safety and efficacy of Cidecin(R) (daptomycin for injection) in the EDGE(TM) (Evaluation of Daptomycin against Gram-positive Entities) clinical trial program and has broadened its pipeline to include multiple pre-clinical drug candidates, including an oral version of ceftriaxone (OCTX), a broad-spectrum cephalosporin antibiotic, and CAB-175, a next generation cephalosporin antibiotic with demonstrated in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). The company is engaged in a strategic partnership with Novartis Pharma AG for the discovery and development of novel antiinfectives.
CV Therapeutics, Inc. (CVT) 3172 Porter Drive Palo Alto, California 94304
CV Therapeutics is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has four compounds in clinical trials. If approved by the FDA, Ranexa would represent the first new class of anti-anginal therapy in more than 20 years. Tecadenoson, an A1-adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. CVT-3146, a selective A2A-adenosine receptor agonist, is being developed for potential use as a pharmacologic stress agent in cardiac perfusion imaging studies. Adentri(TM), an A1-adenosine receptor antagonist for the potential treatment of acute and chronic congestive heart failure, is licensed to Biogen, Inc. Email: info@cvt.com
Cyclacel Limited Dundee Technopole Dundee, United Kingdom DD1 5JJ
Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel's discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, state-of-the-art RNAi functional genomics, chemogenomics and clinical biomarker technologies to rapidly deliver new drugs. Email: info@cyclacel.com
Cytogen Corporation Princeton, New Jersey
Cytogen Corporation is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and BrachySeed(TM) Pd-103 (two uniquely designed, next- generation radioactive seed implants for the treatment of localized prostate cancer); and NMP22(R) BladderChek(TM) (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet(R), a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which the company receives royalties on product sales through Berlex Laboratories, the U.S. affiliate of Schering AG Germany, which markets the product in the United States.
Dendreon Corporation Seattle, Washington
Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The Company's lead investigational product candidate, Provenge®, is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial for the potential treatment of androgen independent prostate cancer. In addition to its therapeutic vaccines in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. Note: Acquisition of Corvas International approved by Dendreon shareholders on 7/29/2003. Email: business@dendreon.com
diaDexus, Inc. South San Francisco, California
diaDexus, Inc., a privately held biotechnology company, is focused on the discovery, development and commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value. diaDexus utilizes genomics and bioinformatics to identify numerous disease-associated molecular targets. Email: pr@diadexus.com
DOR BioPharma, Inc. 1691 Michigan Ave Suite 435 Miami, Florida 33139
DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of biodefense vaccines and therapeutics for areas of unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin. DOR's lead therapeutic product, orBec® (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed to treat inflammation in the mucosal lining of the intestine and stomach that can occur following allogeneic bone marrow and stem cell transplants. Email: info@dorbiopharma.com
DOV Pharmaceutical Inc. Hackensack, New Jersey
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, cardiovascular and urological disorders. The Company has five product candidates in clinical trials addressing therapeutic indications with significant unmet needs. In addition to bicifadine for pain, those candidates address insomnia (indiplon, under license to Neurocrine and in Phase III development), anxiety (ocinaplon, joint ventured with Elan), angina and hypertension (joint development with Biovail) and depression (DOV 216-303, being developed in-house).
Dynavax Technologies 717 Potter Street, Suite 100 Berkeley, California 94710
Dynavax Technologies is a biopharmaceutical company developing innovative products for treating and preventing allergy, inflammation-mediated diseases, infectious diseases and cancer. The company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Because ISS target the cause of many diseases - a faulty immune response - they represent a potential breakthrough in the treatment of immune-related disorders. ISS therapy is expected to be more effective, longer lasting, safer and more convenient than current treatments. With four ISS-based product candidates currently in clinical trials, Dynavax has established a leadership position in the research and development of novel therapies for a range of major immune-related disorders.
Email: contact@dvax.com
ECR Pharmaceticals Richmond, Virginia
ECR PHARMACEUTICALS markets both prescription and consumer products (which may be purchased without a prescription). Current therapeutic categories include oral analgesics, topical arthritis pain relievers, cough and cold medications, as well as products for seasonal allergies and contact dermatitis. Products are marketed nationwide, with most of ECR’s sales staff currently located in the southeastern and southwestern United States.
Eisai, Inc. Teaneck, New Jersey
Eisai selects products for worldwide development that bring value to patients and their families and meet treatment needs. Worldwide, Eisai Co., Ltd. and its affiliates spend more than 15% of its revenue on research and development. Areas of study include immunology, endocrinology, gastroenterology, neurology, cardiology, pulmonology and oncology.
Elan Corporation, PLC Dublin, Ireland
Elan Corporation, plc (Elan) began in 1969 with a vision: to approach the challenge of drug delivery from an entirely new angle—that of controlled absorption of a drug by the patient’s body. Over the years, Elan transitioned to become a world leader in drug delivery and specialty pharmaceuticals.
Today, Elan has become a fully integrated biopharmaceutical company, pioneering exciting new research and development in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cancer, pain management and autoimmune diseases. It is focused on the discovery, development, and marketing of products and services in neurology, pain management, oncology, infectious disease and dermatology and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies.
Encysive Pharmaceuticals 6700 West Loop, 4th Floor Bellaire, Texas 77401
Encysive Pharmaceuticals is a pharmaceutical company that discovers, develops and commercializes small molecule drugs aimed at cardiovascular and inflammatory diseases. Our research strategy focuses on the vascular endothelium, because of its importance in the evolution of a number of serious diseases for which current therapies are inadequate. Today, we are capitalizing on the approval of our first product, Argatroban, the R&D assets embedded in a full pipeline of promising drug candidates, and our growing clinical and business expertise to make the transition to a successful commercial operation. [Formerly Texas Biotechnology, name changed May 2003]
Email: info@encysive.com
Endo Pharmaceuticals Inc. Chadds Ford, Pennsylvania
A wholly owned subsidiary of Endo Pharmaceuticals Holdings (Nasdaq: ENDP, ENDPW), Endo Pharmaceuticals is a fully integrated specialty pharmaceutical company with market leadership in pain management products. The company researches, develops, produces and markets a broad product offering of both branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike.
Enzo Biochem, Inc. New York, New York
A leading biotechnology company engaged in the research, development, manufacturing and marketing of innovative health care products. Its three business subsidiaries are focused on early diagnosis, prevention and therapeutic treatment of disease. The company has concentrated on the development of enabling technologies in the areas of gene modification and gene regulation. In focusing its efforts in these areas, and in achieving patent protection for its technologies, Enzo has established the basis for a broad category of novel products, both diagnostic and therapeutic.
Enzon Pharmaceuticals, Inc. Bridgewater, New Jersey
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat life-threatening diseases. The company has developed or acquired a number of marketed products, including ABELCET, which is marketed in North America by Enzon, and PEG-INTRON, marketed by Schering-Plough.
Enzon’s product-focused strategy includes an extensive drug development program that leverages the Company’s PEG modification and single-chain antibody (SCA®) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products, projects, and technologies. Enzon has several drug candidates in various stages of development, independently and with partners.
Eon Labs, Inc. Laurelton, New York
Eon Labs, Inc. is a generic pharmaceutical company engaged in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products. An industry leader in obtaining Abbreviated New Drug Application, or ANDA, approvals from the U.S. Food and Drug Administration for new generic pharmaceutical products, Eon Labs' product line consists of nearly 250 products from more than 100 medications. Eon Labs' experienced management team utilizes an integrated approach to select and develop generic pharmaceutical products in both niche and high volume markets in order to be the first generic alternative to market and to obtain favorable market share. Eon Labs focuses on drugs in a broad range of solid oral dosage forms, utilizing both immediate and sustained release delivery.
Esperion Therapeutics, Inc. 3621 South State Street Ann Arbor, Michigan 48108
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, “HDL-C”, also known as the “good” cholesterol.
The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company’s product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases. Email: info@esperion.com
EXACT Sciences Corporation 100 Campus Drive Marlborough, Massachusetts 01752
EXACT Sciences Corporation is an applied genomics company located in Maynard, MA. Founded in 1995, the company's mission is to play a leading role in the eradication of common cancers by applying advances in the field of genomics to facilitate early detection of disease. EXACT Sciences believes its proprietary, genomics-based technologies will revolutionize the early detection of colorectal and other common cancers. EXACT Sciences believes that widespread and periodic application of these non-invasive technologies will reduce the mortality, morbidity and healthcare costs associated with these diseases. Email: info@exactsciences.com
FibroGen Inc. South San Francisco, California
FibroGen has developed the only commercially viable method known to produce human collagen and human gelatin in recombinant systems.
FibroGen will exploit this technology by becoming both a bulk product supplier for the pharmaceutical and medical device industries as well as a developer and commercializer of injectable products, wound management products, and gelatin stabilizers.
FibroGen's corporate collaborations include a partnership with Taisho Pharmaceutical Company of Japan to discover and develop human monoclonal antibody therapeutics for renal fibrosis and chronic transplant rejection.
First Horizon Pharmaceutical Corporation Alpharetta, Georgia
First Horizon Pharmaceutical Corporation is a specialty pharmaceutical Company that markets prescription products in four therapeutic areas: cardiology, obstetrics and gynecology, pediatrics and gastroenterology. The Company has a portfolio that includes 17 branded prescription products of which 7 are actively promoted to high-prescribing physicians through its nationwide marketing and sales force.
Fujisawa Healthcare, Inc. Deerfield, Illinois
Fujisawa Healthcare, Inc., headquartered in Deerfield, Illinois is a subsidiary of Fujisawa Pharmaceutical Company, Ltd., based in Osaka, Japan. Fujisawa Pharmaceutical Co., Ltd., founded in 1894, is a leading pharmaceutical manufacturer and is actively developing its international operations in North America, Europe and Asia. Being the world's largest pharmaceutical market, the United States naturally occupies a preeminent position at the core of Fujisawa's international strategy.
Fujisawa Pharmaceuticals merged with Yamanouchi Pharmaceuticals in April 2005 to become Astellas Pharma Inc.
GelTex Pharmaceuticals, Inc. (a Genzyme General Business) Waltham, Massachusetts
GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialysis patients. In addition, WelChol(TM) brand colesevelam hydrochloride was granted marketing approval by the FDA in May 2000, for the treatment of hypercholesterolemia, a condition characterized by undesirably high blood cholesterol levels. (WelChol is a trademark of Sankyo Pharma Inc., our partner for commercializing WelChol)
Gen-Probe Incorporated San Diego, California
GEN-PROBE currently markets several product lines, including the PACE® 2 System, the GEN-PROBE® AMPLIFIED™ Direct Tests, and the AccuProbe® System. Other products are currently under development or awaiting FDA approval. GEN-PROBE products continue to set the standard for DNA probe technology in the diagnostic industry, with assays for sexually transmitted diseases, microbial infectious diseases, and culture identification. In addition, we offer a full line of supporting instrumentation.
Genaera Corporation 5110 Campus Drive Plymouth Meeting, Pennsylvania 19462
Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. Genaera has three products in development addressing substantial unmet medical needs in major pharmaceutical markets. These include squalamine, an anti-angiogenic treatment for eye disease and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease. Email: info@genaera.com
Genaissance Pharmaceuticals, Inc. Five Science Park New Haven, Connecticut 06511
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA-based diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Email: info@genaissance.com
Genentech, Inc. South San Francisco, California
Genentech, the founder of the biotechnology industry, is a company with a quarter-century track record of delivering on the promise of biotechnology. Today, Genentech is among the world's leading biotech companies -- with 10 protein-based products on the market for serious or life-threatening medical conditions. Genentech's product pipeline includes approximately 20 projects that focus primarily on oncology, cardiovascular disease and immunological disease. With its world-renowned research organization, unparalleled development and manufacturing capabilities, highly sophisticated commercial organization, and close to 5,000 competent, creative and enthusiastic employees, Genentech continues to transform the possibilities of biotechnology into improved realities for patients. For more general information about the company, visit our corporate overview section.
Genesis Bio-Pharmaceuticals Hackensack, New Jersey
Genesis Bio-Pharmaceuticals was established in 1990 as a Pharmaceutical marketing and distribution organization specializing in providing plasma derivative products, transplant products, vaccines and specialty surgical products as well as unique distribution services to hospitals, clinics, home IV therapy centers, pharmacies and physician offices. Genesis Bio-Pharmaceuticals has relationships with most major plasma derivative manufacturers as well as with many other vaccine and specialty pharmaceutical product organizations.
Genetronics Biomedical Corporation San Diego, California
Genetronics Biomedical Corporation is a leader in electroporation therapy with 216 patents issued, allowed, or pending. The Company utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, vaccines, and gene therapy. In oncology, Genetronics has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer. In gene therapy, Genetronics has several collaborations with major biotechnology and pharmaceutical companies for the delivery of therapeutic genes or vaccines using electroporation. Genetronics' BTX Division, a leader in molecular delivery, features electroporation and electro fusion technology for research laboratory markets worldwide.
Geneva Pharmaceuticals (Member of the Novartis Group) Broomfield, Colorado
Geneva Pharmaceuticals is one of the leading generic pharmaceutical manufacturers and marketers in the United States. Recent acquisitions of Invamed (now called Geneva Pharmaceuticals Technology Corporation, or GPTC) and the marketing rights to Apothecon’s anti-infective and generic product lines have strengthened our position as a market leader.
GenoMed St. Louis, Missouri
GenoMed is a Next Generation Disease Management (tm) company that uses medical genomics to improve patient outcomes. GenoMed is working to translate knowledge of medical genomics (the study of which genes cause disease) into clinical practice: developing better drugs, using existing drugs for new indications, and identifying diseases before symptoms arise. By studying disease genes, we hope to make medicine less invasive and more proactive.
Genta Two Connell Drive Berkeley Heights, New Jersey 07922
Genta is a biopharmaceutical company that identifies, develops, and commercializes drugs for the treatment of patients with cancer. We market drugs to a physician-centered healthcare system. Employees and shareholders are rewarded by a corporate culture that values excellence in performance, innovation, quality, leadership and absolute integrity.
Genta"s rich pipeline is anchored by 4 key components: ;Antisense Technology; Androgenics Products; Gallium Products; and Decoy Aptamers. The products from each of these platforms address significant unmet medical needs, in markets that individually exceed $1 billion dollars annually. The Company"s lead antisense compound, GenasenseTM, is currently in late-stage clinical trials for treatment of melanoma, multiple myeloma, chronic lymphocytic leukemia and non-small cell lung cancer. Email: info@genta.com
GenVec, Inc. Gaithersburg, Maryland
GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an exciting product portfolio, which includes TNFerade™ for the treatment of cancer and BIOBYPASS® angiogen for the treatment of cardiovascular disease.
Genzyme Biosurgery Cambridge, Massachusetts
Genzyme Biosurgery (Nasdaq: GZBX) develops and commercializes implantable biotechnology products. It is focused on three medical areas - orthopaedic disease and injury, serious heart disease, and improving the outcomes of surgery. Within these areas, our portfolio includes a range of marketed biotherapeutics, biomaterials and medical devices, with many more in the pipeline.
Genzyme General Cambridge, Massachusetts
Genzyme General, one of the three divisions of Genzyme Corporation, develops and commercializes innovative solutions for major unmet medical needs of patients with genetic and serious debilitating diseases. Genzyme General is composed of five operating units: Genzyme Therapeutics, Genzyme Genetics, Genzyme Diagnostics and Genzyme Pharmaceuticals.
Genzyme Molecular Oncology Cambridge, Massachusetts
Genzyme Molecular Oncology (Nasdaq: GZMO) is positioned where the power and promise of genomics and biotechnology meet. It is utilizing its powerful proprietary functional genomics and antigen discovery technology platforms to develop novel cancer products and to create a deep and promising product pipeline focused on cancer vaccines and angiogenesis inhibitors. It is shaping these new therapies through the integration of its genomics, gene and cell therapy, small-molecule drug discovery, and protein therapeutic capabilities.
Gilead Sciences, Inc. Foster City, California
At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs focus on nucleotides, liposomes, durable HIV inhibitors and other small molecules.
To date, Gilead's portfolio includes six marketed products and several clinical and preclinical products in development.
Glades Pharmaceuticals, LLC Suwanee, Georgia
Glades Pharmaceuticals is the generic division of Stiefel Laboratories, a company focusing specifically on products for the skin since its inception in 1847. Being part of the world’s leading dermatology company has helped Glades grow quickly since we launched our first product in 1991. Glades is now the leading dermatology-only generic company with a variety of topical steroids, acne drugs, antibiotics, skin bleaches, and OTC’s.
GlaxoSmithKline Brentford, Middlesex, United Kingdom
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
Gliatech Inc. Cleveland, Ohio
Gliatech Inc. is engaged in the discovery and development of biosurgery and pharmaceutical products. The biosurgery products include ADCON(R) Gel (ADCON(R)-L & T/N) and ADCON(R) Solution, which are biopolymer medical devices designed to inhibit scarring and adhesions following surgery. Gliatech's pharmaceutical product candidates include proprietary monoclonal antibodies designed to inhibit inflammation.
Global Pharmaceuticals Philadelphia, Pennsylvania
Global Pharmaceuticals is the generics marketing division of IMPAX Laboratories, Inc., a technology-based specialty pharmaceutical company applying its formulation expertise and drug-delivery technology to the development of controlled-release and niche products. Global’s multi-source product line consists of a growing range of solid oral prescription pharmaceuticals, distributed primarily through drug wholesalers, distributors, warehousing chains, and managed healthcare organizations.
GlycoGenesys, Inc. Boston, Massachusetts
GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life threatening or debilitating diseases. The company's lead drug candidate, GCS-100, formerly known as GBC-590, is a potential treatment for multiple forms of cancer.
Guilford Pharmaceuticals Inc. Baltimore, Maryland
Guilford Pharmaceuticals Inc. was founded in July 1993 by Scios Nova Inc., Dr. Solomon H. Snyder and Dr. Craig R. Smith to discover and develop novel pharmaceutical and biopolymer-based products that are intended to offer new and better treatments for serious medical conditions like Parkinson's disease, Alzheimer's disease, cancer and diabetic peripheral neuropathy. To focus its efforts, the company has developed two innovative technology platforms that have already spawned one commercial product and more than half a dozen novel product candidates.
Gynétics Inc.
Gynétics' first major product was the PREVEN™ Emergency Contraceptive Kit, which was introduced in September, 1998. The original package has been supplemented with the addition of the PREVEN™ Emergency Contraceptive Pills package in May 2000. Gynétics also markets the GynoSampler® Endometrial Curette, a diagnostic endometrial tool that plays an increasingly important role within the in-office diagnostic environment. Endometrial sampling should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal uterine bleeding and as surveillance of all women taking estrogen as part of hormone replacement therapy.
Hoffmann-La Roche, Inc. Nutley, New Jersey
Hoffmann-La Roche Inc. is the U.S. prescription drug unit of the Roche Group, a leading international health care company with principal businesses in pharmaceuticals, diagnostics and vitamins. Roche provides more than 35 medications in the United States in major therapeutic areas including AIDS, cardiovascular diseases, central nervous system disorders, dermatology, infectious diseases, oncology and transplantation.
Hyseq Pharmaceuticals, Inc. Sunnyvale, California
Hyseq Pharmaceuticals, Inc. is engaged in research and development of novel biopharmaceutical products from its collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. This platform provided a significant advantage in discovering novel, rarely-expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq intends to further elucidate the physiological roles of its proprietary novel genes. Hyseq's database includes genes which encode a number of therapeutically important classes of molecules including chemokines, growth factors, stem cell factors, interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets.
IGEN International Inc 16020 Industrial Drive Gaithersburg, Maryland
IGEN develops and markets biological detection systems based on its proprietary ORIGEN technology, which provides a unique combination of sensitivity, reliability, speed and flexibility. ORIGEN-based systems are used in a wide variety of applications, including clinical diagnostics, pharmaceutical research and development, life science research, biodefense testing and testing for food safety and quality control. These systems are marketed globally by IGEN and its licensees and/or distributors. Merger with Roche completed 2/13/2004.
igeneon Vienna, Austria
igeneon is a biopharmaceutical company which focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin. It has built up a well balanced portfolio of cancer immunotherapies. The three key products, which are broadly applicable, are undergoing clinical trials up to Phase II/III. A number of innovative follow-up projects are also in the pipeline. igeneon is privately financed. Investors include 3i, Novartis Venture Fund and Deutsche Venture Capital.
Email: ursula.mayer@igeneon.com
ImClone Systems Incorporated New York, New York
ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments, designed to address the medical needs of patients with a variety of cancers. The Company's three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Somerville, New Jersey. Email: media@imclone.com
ImmunoGen, Inc. Cambridge, Massachusetts
ImmunoGen, Inc. (Nasdaq: IMGN) develops innovative biopharmaceuticals for the treatment of cancer. The Company's proprietary TAP technology combines extremely potent, cell-killing agents with monoclonal antibodies that recognize and bind specifically to tumor cells. This targeted delivery technology increases the potency of these cancer-specific antibodies, which allows the drugs to kill cancer cells with minimal harm to healthy tissue. ImmunoGen’s TAP technology is designed to address the two fundamental limitations associated with traditional chemotherapeutics: efficacy and tolerability.
IMPAX Laboratories, Inc. Hayward, California
IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division.
Incara Pharmaceuticals Corporation 4401 Research Commons, Ste 200 Research Triangle Park, North Carolina 27709
Incara Pharmaceuticals Corporation is focused on a new class of disease-modifying small molecules, the catalytic antioxidants. Oxygen derived free radicals are a common step in neuronal death resulting from a variety of causes. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurologic disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease) and stroke and in other non-neurological indications such as cancer radiation therapy, chronic bronchitis and asthma. Email: info@incara.com
Incyte Corporation Wilmington, Delaware
Incyte is a Wilmington, Delaware-based drug discovery and development company with a growing pipeline of novel small molecule drugs to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset, is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. Currently, Incyte has four drug discovery programs underway, an extensive intellectual property portfolio and a proteomic information business based in Beverly, Massachusetts.
Innapharma, Inc. Park Ridge, New Jersey
Innapharma, Inc. is engaged in the development of a series of "small chain" peptide-based products to treat central nervous system disorders, with the Company's leading product being an antidepressant. Innapharma also has a series of new tetracycline molecules in early development. These molecules may have activity against certain cancers and rheumatoid arthritis, in addition to antibiotic activity. Initial testing has already provided encouraging results in pre-clinical models.
Integrity Pharmaceutical Corporation Fishers, Indiana
Integrity Pharmaceutical's prescription products treat lower urinary tract pain and spasms; and provide women in childbearing years optimal prenatal nutrition. Our generic drugs are valuable for patients and health care providers because they represent high quality, low cost alternatives to many of today's commonly prescribed medications.
InterMune, Inc. Brisbane, California
InterMune is a commercially driven biopharmaceutical company focused on the marketing, development and applied research of life-saving therapies for pulmonary disease, infectious disease and cancer. We market three products: Actimmune® (Interferon gamma-1b), Infergen® (Interferon alfacon-1), and Amphotec® (Amphotericin B Cholesteryl Sulfate Complex for Injection), and have a late-stage development pipeline including 15 active clinical trials. Our lead clinical programs are focused on developing Actimmune for idiopathic pulmonary fibrosis, ovarian cancer and liver fibrosis; developing oritavancin as a novel antibiotic for the treatment of serious Gram-positive infections and developing a pegylated form of Infergen (PEG-Infergen) for chronic hepatitis C infections.
Introgen Therapeutics, Inc. Austin, Texas
Introgen Therapeutics is a leader in the development and production of gene-based drugs for the treatment of cancer and other diseases.
Inverness Medical Innovations Waltham, Massachusetts
Inverness Medical Innovations manufactures and sells products for the women’s health and nutritional product markets and is engaged in the business of developing, acquiring, manufacturing, and marketing advanced medical device technologies. The Company’s women’s health and nutritional products are distributed to consumers through established retail distribution networks such as Wal-Mart, Walgreens and CVS.
Invitrogen Corporation Carlsbad, California
Invitrogen Corporation develops, manufactures and markets research tools in kit form for biotechnology researchers and companies worldwide. Our goal is to assist life scientists in accomplishing biological procedures faster, more reliably and in a more cost effective manner. We offer thousands of products and services that simplify and improve gene cloning, gene expression, and gene analysis techniques for corporate, academic and government entities.
IVAX Pharmaceuticals, Inc. Miami, Florida
IVAX Pharmaceuticals, Inc develops, manufactures, and markets brand equivalent (generic) pharmaceutical products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home providers, and government agencies in the United States. IVAX Pharmaceuticals is a subsidiary of Miami-based IVAX Corporation, which is engaged in the research, development, manufacture, and marketing of branded and brand equivalent pharmaceuticals worldwide. IVAX Pharmaceuticals is one of the premier brand equivalent drug companies in the U.S., with an estimated 6% of the domestic market. IVAX Pharmaceuticals offers a balanced product portfolio featuring specialty generics and a broad range of other brand equivalent products that meet the needs of its customers. Under the "IVAX Pharmaceuticals" and "Goldline" trade names, IVAX Pharmaceuticals manufactures and markets approximately 50 brand equivalent prescription drugs in capsule or tablet forms in an aggregate of approximately 120 dosage strengths.
Janssen Pharmaceutica Products, L.P. Titusville, New Jersey
Janssen Pharmaceutica Products, L.P., is a company driven by a dedication to product innovation, customer focus and employee/organizational excellence. In the United States, medications now available in pharmacies include drugs for the treatment of psychotic disorders, such as schizophrenia; mild to moderate Alzheimer's disease; chronic pain; fungal infections; erosive gastroesophageal reflux disease (GERD); and duodenal ulcers. Janssen is proud to be a member of the Johnson & Johnson family of companies.
Johnson & Johnson New Brunswick, New Jersey
Johnson & Johnson, with approximately 104,500 employees, is the world's most comprehensive and broadly-based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical and medical devices and diagnostics markets. Johnson & Johnson has more than 197 operating companies in 54 countries around the world, selling products in more than 175 countries.
King Pharmaceuticals, Inc. Bristol, Tennessee
King Pharmaceuticals is a vertically integrated pharmaceutical company that manufactures, markets, and sells primarily branded prescription pharmaceutical products. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry created by cost containment initiatives and consolidation among large global pharmaceutical companies. King's strategy is to acquire branded pharmaceutical products and to increase their sales by focused promotion and marketing and through product life cycle management.
Eli Lilly and Company Indianapolis, Indiana
Eli Lilly and Company creates and delivers innovative medicines that enable people to live longer, healthier and more active lives.
Lilly products treat depression, schizophrenia, diabetes, cancer, osteoporosis and many other diseases. They create value for patients, health-care providers and payers, and reduce the cost of disease.
Ligand Pharmaceuticals San Diego, California
Ligand is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small molecule drugs to address critical, unmet medical needs.
LigoCyte Pharmaceuticals, Inc. 920 Technology Boulevard, Suite C Bozeman, Montana 59718
LigoCyte, established in 1998, focuses on cell-surface receptors that govern the way the human immune system recognizes and responds to inflammatory events and infectious organisms. The company's immunomodulatory drug discovery and development activities support its pipeline of therapeutic candidates. LigoCyte has developed the ProteoFlow® high content assay technology for the evaluation of inhibitors in human cells under physiologic flow conditions. This powerful technology provides the company with a highly effective tool for predicting drug behavior in animals and humans, streamlining the drug development process and reducing risk associated with dosing efficacy. Email: ligocyte@ligocyte.com
Mallinckrodt, Inc. Hazelwood, Missouri Tyco Healthcare/Mallinckrodt, based in St. Louis, Missouri, manufactures and markets medical products. Our mission is to improve healthcare for patients worldwide by providing superior products that sustain breathing, diagnose disease and relieve pain. We are committed to producing products that bring better healthcare to patients, more value to medical professionals, greater opportunity to employees, and increased earnings to reward Tyco shareholders.
Maxim Pharmaceuticals San Diego, California
Maxim Pharmaceuticals is a global bio-pharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers, hepatitis and other liver diseases.
MedImmune, Inc. Gaithersburg, Maryland
MedImmune, Inc. is a fully integrated biotechnology company founded in 1988. It is focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation, and cancer. The company's capabilities span the entire spectrum of pharmaceutical development, including discovery research, clinical development, data analysis, regulatory affairs, quality control, manufacturing, and sales and marketing.
Memory Pharmaceuticals Corp. 100 Philips Parkway Montvale, New Jersey 07645
Memory Pharmaceuticals, a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer’s Disease, depression, schizophrenia, vascular dementia, Mild Cognitive Impairment, and memory impairments associated with aging. The Company’s customized drug development infrastructure emphasizes rigorous target identification and compound screening procedures, medicinal chemistry, neurobehavioral biology, and sophisticated IT systems. Advanced capabilities and in-house expertise in drug discovery and development have allowed the Company to generate a diverse pipeline of promising drug development programs.
Email: info@memorypharma.com
Merck & Company, Inc. Whitehouse Station, New Jersey
Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health. The Merck-Medco Managed Care Division manages pharmacy benefits for more than 40 million Americans, encouraging the appropriate use of medicines and providing disease management programs.
Millennium Pharmaceuticals, Inc. Cambridge, Massachusetts
Millennium Pharmaceuticals currently markets two products, the cardiovascular drug INTEGRILIN® (eptifibatide) Injection and the oncology drug VELCADE™ (bortezomib) for Injection. These are examples of the types of drugs Millennium expects to develop in four key therapeutic areas:
Cancer
Cardiovascular diseases
Inflammation
Metabolic disorders
The company also has a significant number of investigational drugs at various stages of clinical and preclinical development, as described in the R&D section of this website, and played a significant role in bringing the oncology drug Campath® (alemtuzumab) Injection to market. Email: info@mlnm.com
Miravant Medical Technologies 336 Bollay Drive Santa Barbara, California 93117
Miravant Medical Technologies specializes in pharmaceuticals and devices for photoselective medicine, developing its proprietary PhotoPoint photodynamic therapy (PDT) for large potential markets in ophthalmology, dermatology, cardiovascular disease and oncology. PhotoPoint PDT uses photoreactive (light-activated) drugs to selectively target diseased cells and blood vessels. Email: info@miravant.com
Molnlycke Health Care Goteborg, Sweden
Mölnlycke Health Care is one of the world’s leading manufacturers of single-use surgical products – patient drapes, instrument drapes and surgical gowns, caps and masks for operating staff. The group also has a strong international standing in the professional wound care sector, with a wide range of products for the treatment of surgical wounds, chronic wounds and burns.
Total annual sales are at present SEK 4,500M and the company has app. 4,000 employees. Of these, about 3,300 are involved in production at factories in Belgium, Finland, Mexico, Thailand and Czech Republic.
Headquarters in Göteborg, Sweden is home to all group staff functions as well as business area management, sales management and Global Supply, which includes, e.g procurement, logistics and IT.
The major shareholders in Mölnlycke Health Care are Nordic Capital and the Sixth National Pension Fund.
Two business areas:
Operations are divided into two business areas – Surgical and Wound Care. Surgical business area products are sold under the brand names Klinidrape® and BARRIER®. Wound Care business area products are sold under the Tendra® brand.
Sales and marketing:
Sales and marketing of both business areas are the responsibility of three joint organisations, one for the US, one for Europe and one for other markets. Twenty subsidiaries and several branch sales offices and distributors are included in the organisation.
Myconostica South Court, Sharston Road Manchester, United Kingdom M22 4SN
Myconostica Ltd develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life threatening invasive fungal infections.
Myconostica have used advances in molecular techniques such as real time PCR to develop a range of assays for the rapid, accurate and sensitive detection of fungi such as Aspergillus spp and Pneumocystis.
Evidence shows that an early diagnosis of invasive fungal infection significantly improves the chance of survival. Tests provided by Myconostica will aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease reduces the hospitalisation and treatment costs associated with invasive fungal disease.
Email: mycoinfo@myconostica.co.uk
Mylan Laboratories Inc. 1500 Corporate Drive Suite 400 Canonsburg, Pennsylvania 15317
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary prescription products. Mylan markets its branded pharmaceuticals through Bertek Pharmaceuticals Inc. Bertek operates as a stand-alone proprietary pharmaceutical company with independent clinical development, business development and sales and marketing efforts. Bertek is a transitional pharmaceutical company that will enable Mylan to grow from a traditional generic company to a proprietary based company. The Company's strategy is to optimize marketing and sales through a targeted therapeutic focus on neurology, dermatology and cardiology, thereby enabling our field sales representatives to concentrate on a narrow physician call base, as well as developing new products as trading stock for other Bertek products. Bertek's vision is to be a growth oriented, highly profitable pharmaceutical company that efficiently commercializes significant improvements to human healthcare.
Email: customerservice@mylanlabs.com
NaPro BioTherapeutics, Inc. 4840 Pearl East Circle, #300W Boulder, Colorado 80301
NaPro BioTherapeutics, Inc., is a life science company focused in two distinct therapeutic areas: the development of proprietary anti-cancer agents and the development of genomic therapies for inherited disease, primarily through the use of our novel "gene editing" technology.
Email: info@naprobio.com
Nektar Therapeutics San Carlos, California
Nektar Therapeutics (NASDAQ:NKTR) provides a portfolio of leading drug delivery solutions that enable the development of high-value pharmaceutical products.
Formed through the fusion of Inhale Therapeutic Systems, Shearwater, and Bradford Particle Design, our company offers a suite of leading drug delivery technologies that encompasses molecule engineering including advanced pegylation, particle engineering comprising both pulmonary particle technology and supercritical fluid technology (SCF), and advanced drug delivery solutions for oral, injectable, and pulmonary administration.
NeoGenesis Pharmaceuticals, Inc. 840 Memorial Drive Camgridge, Massachusetts 02139
NeoGenesis Pharmaceuticals, Inc. is a drug discovery company focused on using its proprietary drug discovery technologies to discover and develop a portfolio of small molecule-based drugs, both for itself and for its collaboration partners. The company's universal, unbiased, affinity-based technologies, coupled with millions of diverse medicinally relevant compounds, provide an unmatched efficiency in lead discovery and optimization. NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid and universal affinity-based system for identifying and optimizing novel drug leads. Coupled with the company's NeoMorph compound library, consisting of more than 10 million diverse medicinally relevant small molecules, ALIS enables the identification of novel and selective drug leads against validated and emerging new genomic targets. Email: info@neogenesis.com
NeoRx Corporation 300 Elliott Avenue West, Suite 500 Seattle, Washington 98119
NeoRx is a cancer therapeutics company developing products for targeted delivery of anti-cancer agents, including radiopharmaceuticals, to tumor sites. Email: IR@neorx.com
Neurion Pharmaceuticals, Inc. 180 North Vinedo Avenue Pasadena, California 91107
Neurion Pharmaceuticals, Inc. is a privately held, development-stage pharmaceutical company that is focused on the discovery of novel drugs for central nervous system (CNS) diseases and other disorders associated with ion channels. The Company uses its proprietary discovery platform technology to understand the structural basis of drug-ion channel interactions, and to design safer and more effective drugs by exploiting this knowledge. Email: billr@neurionpharma.com
Neurocrine Biosciences, Inc. San Diego, California
Neurocrine Biosciences is a biopharmaceutical company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, multiple sclerosis, insomnia, brain cancer, obesity and diabetes.
Novartis Pharmaceuticals New York, New York
Novartis is a global company that touches your life in ways you might not have imagined. Our employees make products that range from life-saving drugs for organ transplantation to state-of-the-art contact lenses, from affordable generic medicines to a famous name in baby food, from trusted over-the-counter brands against the common cold to products that protect farm animals and your beloved pets from parasites and disease. What do these business areas have in common? They are all powered by science and innovation. Novartis invests approximately 4 billion Swiss francs every year in research and development. We are exploring new scientific horizons and applying the latest technologies to lead future breakthroughs.
Novo Nordisk Plantation, Florida
Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is the world leader in diabetes care. In addition, Novo Nordisk has a leading position in areas such as haemostasis management, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
NPS Pharmaceuticals Salt Lake City, Utah
NPS Pharmaceuticals is engaged in the discovery and development, and is preparing for the commercialization of therapeutic small molecules and recombinant proteins.
Current product candidates include treatments for bone and mineral disorders (osteoporosis & hyperparathyroidism), gastrointestinal disorders (GI) and central nervous system disorders (CNS). Our objective is to build a profitable company by using our scientific development and marketing expertise, which will allow us and the patients who use our drugs, to reap the value of our efforts. We are creating a diversified pipeline of products in all stages of development from discovery research, to preclinical testing, to clinical trials.
Nymox 230 West Passaic Street Maywood, New Jersey 07607
Nymox Pharmaceutical Corporation is a biopharmaceutical company based in Maywood, New Jersey and Saint Laurent, Quebec. It has two subsidiaries, Nymox Corporation and Serex, Inc.
Nymox specializes in the research and development of therapeutics and diagnostics for the aging population with an emphasis on Alzheimer's disease.
Nymox was incorporated in 1989 and became a public company in 1995. Nymox was founded around a group of distinguished career scientists with long established interests in brain diseases and Alzheimer’s disease in particular.
Nymox is the first company to have successfully developed an accurate peripheral test for this devastating disorder, the AlzheimAlert™ test. Nymox’s strong scientific relationships have led to the development every year of at least one major new project initiative. Nymox currently markets its AlzheimAlert™ test to physicians in the U.S. and its NicAlert™ test for tobacco exposure both in the U.S. and Japan. Nymox has an exciting pipeline of drugs in development and a proprietary antimicrobial treatment against deadly E. coli contamination. Nymox also has a line of other “Alert” products (such as OsteoAlert™ for osteoporosis) in development, as well as a unique proprietary diagnostic platform technology. Email: info@nymox.com
Organon USA Roseland, New Jersey
Organon is a renowned global pharmaceuticals company with a strong commitment to human health care. The company develops and produces innovative prescription medicines for women's health, mental health, cardiovascular disease, immunology, and anesthesiology. Organon products are sold in over 100 countries, more than half of which have an Organon subsidiary. Organon was founded in 1923 and is a business unit of the Pharma division of Akzo Nobel, NV. The Pharma division consists of three business units – Organon, Intervet and Diosynth.
Ortho-McNeil Pharmaceuticals Raritan, New Jersey
Ortho-McNeil, a Johnson & Johnson company, is based in Raritan, NJ. The company markets pharmaceutical products in several therapeutic categories including infectious diseases, central nervous system, wound healing, urology and women's health.
OSI Pharmaceuticals 58 South Service Road Suite 110 Melville, New York 11747
OSI Pharmaceuticals is a leading biotechnology company focused on the discovery, development, and commercialization of high-quality, next-generation oncology products that both extend and improve the quality-of-life for cancer patients worldwide. OSI has a balanced pipeline of oncology drug candidates that includes both next-generation cytotoxic agents and novel mechanism-based, gene-targeted therapeutics focused in the areas of signal transduction and apoptosis. OSI has a commercial presence in the U.S. oncology market where it exclusively markets Novantrone® (mitoxantrone concentrate for injection) for approved oncology indications and Gelclair(TM) for the relief of pain associated with oral mucositis. Our most advanced drug candidate is Tarceva™ (erlotinib HCl), a small-molecule inhibitor of the epidermal growth factor receptor, or HER1/EGFR. We believe HER1/EGFR inhibitors represent an exciting new class of relatively safe and well-tolerated anti-cancer agents that may have utility in treating a wide range of cancer patients. Tarceva™ is an oral once-a-day small molecule drug designed to specifically block the activity of the HER1/EGFR protein and has demonstrated encouraging indications of anti-cancer activity in single-agent, open label Phase II trials in non-small cell lung cancer, head and neck cancer and ovarian cancer. Tarceva™ is being developed in an alliance with Genentech, Inc. and Roche and is currently in Phase III clinical trials for non-small cell lung cancer and pancreatic cancer. Email: info@osip.com
Perlegen Sciences, Inc. Mountain View, California
Perlegen Sciences, Inc. is a private company that uses high-density, whole-wafer microarray technology in combination with new approaches to sample preparation to scan entire human genomes. The company's first objective is to read 50 different human genomes at a single base resolution, discovering and analyzing the patterns of genetic variation between them. Then, using what it has learned about genome-wide haplotype patterns by reading the first 50 genomes, Perlegen will scan the DNA of thousands of individuals with pharmaceutical partners, in order to associate genetic haplotypes with disease and drug response. The company will also conduct downstream research aimed at elucidating the biology underlying those genotype-phenotype associations in order to accelerate the discovery of new drugs and the modification of existing treatments.
Pfizer, Inc. New York, New York
Pfizer Inc is a research-based, global pharmaceutical company. We discover and develop innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.
Pharmacia Corporation
Pharmacia is a top-tier global pharmaceutical company. We have built a portfolio of outstanding products, led by our key growth drivers: CELEBREX® (celecoxib capsules), CAMPTOSAR® (irinotecan hydrochloride injection), XALATAN® (latanoprost ophthalmic solution), DETROL®LA (tolterodine tartrate extended release capsules), and ZYVOX™ (linezolid injection, tablets, and for oral suspension). Acquisition by Pfizer, Inc. announced in April 2003.
Pharmacyclics, Inc. Sunnyvale, California
Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer and atherosclerosis. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. When activated by various forms of energy, including X-ray and light, these texaphyrins can help to reduce or eliminate the diseased tissue.
PharmaNetics, Inc. Raleigh, North Carolina
PharmaNetics, Inc., a leading biotech company, conceived the term "theranostics," defining an emerging new field of medicine that enables physicians to monitor the effect of antithrombotic agents in patients being treated for angina, myocardial infarction (heart attack), stroke, and pulmonary and arterial emboli. The Company develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. PharmaNetics develops tests based on its proprietary, dry chemistry Thrombolytic Assessment System for its principal target market of managing powerful new drug compounds, some of which may have narrow therapeutic ranges, as well as for monitoring routine anticoagulants.
Plexxikon 91 Bolivar Drive Berkeley, California 94710
Plexxikon is a leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease. Since operations commenced June 2001, Plexxikon has applied its proprietary platform technology to identify and build a portfolio of product opportunities for therapeutic indications in metabolic disorders, cardiovascular disease, inflammation and oncology.
Current Plexxikon programs address disease targets that are already validated in humans, have clear clinical development paths for significant unmet markets, and demonstrate Plexxikon's capability to address side effects and/or enhance the therapeutic profile of current drug treatments.
Plexxikon's discovery process utilizes a number of technologies, including Plexxikon's Scaffold-Based Drug Discovery™ platform. This discovery platform involves structural screening and analysis as one key component providing a significant competitive advantage to other drug discovery approaches. Structural screening is applied at the earliest point in lead finding to address current challenges in pharmaceutical drug discovery today – by enabling the mining of novel chemical space, applying a unique quality filter, and by providing a roadmap for lead discovery and development chemistry. Email: info@plexxikon.com
Pressure BioSciences, Inc. 375 West Street West Bridgewater, Massachusetts 02379
Following the sale of substantially all the assets and selected liabilities of its BBI Diagnostics and BBI Biotech Divisions to SeraCare Life Sciences, Inc. on September 14, 2004, Boston Biomedica changed its name to Pressure BioSciences, Inc (PBI). PBI is a publicly traded, early-stage company focused on the development of a novel technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (35,000 psi and greater) to control bio- molecular interactions. PBI currently holds 13 US and foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. PBI owns a 30% passive investment in Source Scientific, LLC, an instrumentation company that develops and manufactures PBI's PCT equipment, as well as a 4.45% passive investment in Panacos Pharmaceuticals, an antiviral drug discovery and development company.
Email: info@bbii.com
Proneuron Biotechnologies, Inc. Ness-Ziona, Israel
Proneuron is a biopharmaceutical company developing cell therapies and other treatment modalities for neurological, ophthalmological and immune-related disorders such as spinal cord injury, multiple sclerosis, glaucoma, Parkinson's and Alzheimer's diseases. Proneuron's unique technologies, developed at the Weizmann Institute, are based on the modulation of natural mechanisms within the body to address currently incurable disorders.
Purdue Pharma L.P. Stamford, Connecticut
Purdue is part of an international group of associated independent companies engaged in the research, development, production, sales, and licensing of both prescription and over-the-counter medicines and hospital products. The company seeks to continually develop and sell new, high-quality, innovative pharmaceutical preparations, which together with clinical data and medical education create new value for patients and the health care system. Our sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to Purdue products. These products include OxyContin® (oxycodone HCl controlled-release) Tablets, MS Contin® (morphine sulfate controlled-release) Tablets, Uniphyl® (theophylline, anhydrous) Tablets, Chirocaine® (levobupivacaine injection), and the popular over-the-counter Senokot® Laxatives, Betadine® Microbicides, and Betadine® Brand Antibiotics.
Ranbaxy Laboratories Limited Princeton, New Jersey
India's largest pharmaceutical company, Ranbaxy Laboratories Limited, is today well positioned in its quest to become a research-based international pharmaceutical company. Ranbaxy is amongst the top pharmaceutical companies in the world. It has been rated the 11th largest Generic Company Worldwide. The Company exports its products to over 70 countries with ground operations in 25 and manufacturing facilities in 7 countries.
Ribapharm Inc. Costa Mesa, California
Ribapharm is a biopharmaceutical company that seeks to discover, develop, acquire and commercialize innovative products for the treatment of significant unmet medical needs, principally in the antiviral and anticancer areas. NOTE: Acquisition by ICN Pharmaceuticals announced 25 August 2003.
Rubicon Genomics, Inc. Ann Arbor, Michigan
Rubicon Genomics’ novel OmniPlexTM technology reformats naturally-occurring chromosomes into new molecules called Plexisomes™. Plexisomes represent an entire genome as DNA units of controlled length that can be amplified in a highly multiplexed fashion. The unique structure of Plexisomes allows large regions of a genome to be analyzed up to hundreds of times more efficiently than cloning or PCR. Hundreds of thousands of DNA bases can be amplified simultaneously from single loci or multiple loci.
Salix Pharmaceuticals, Inc. Raleigh, North Caroliina
Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to gastroenterologists and their patients.
Our "search and development" efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products that have an existing base of safety and efficacy data for the treatment of gastrointestinal disease. This focus on late-stage products serves to reduce the risk, time and expense Salix invests in products compared to the investment typically associated with the research and early development phases of pharmaceutical products.
Salix has a direct sales force to promote its products to the fastest- adopting, highest-prescribing physicians in the U.S. responsible for treating gastrointestinal disease. We believe that our specialty sales force – and the high level of service we are able to provide - allows us to capitalize on the opportunity to build a franchise with the gastroenterology community. We also believe that our specialty sales force allows us to attain the higher profit margins and benefits of direct control over distribution that comes with selling products directly.
Email: investor.relations@salixpharm.com
SangStat Medical Corporation 6300 Dumbarton Circle Fremont, California 94555
SangStat Medical Corporation is a global biotechnology company focused on immunology and working to discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and immunosuppression areas. NOTE: Acquisition by Genzyme Corporation announced 8/04/2003. Email: bmartin@sangstat.com
sanofi-aventis Group New York, New York
The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris and New York. Email: info@sanofi-aventis.com
Schering-Plough Corporation Kenilworth, New Jersey
As a worldwide, research-based pharmaceutical company, we are engaged in the discovery, development, manufacturing and marketing of new therapies and treatment programs that can improve people's health and extend their lives.
Our primary business involves prescription products in core product categories, including: Allergy and respiratory, Anti-infective and anticancer, Cardiovasculars,
Dermatologicals, Central nervous system and other disorders.
Scios Inc. Sunnyvale, California
Scios Inc. is a biopharmaceutical company developing novel drugs for the potential treatment of cardiovascular and inflammatory diseases. We are distinguished by our disease-based technology platform which integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small-molecule compounds. Scios has received approval from the U.S. Food and Drug Administration to market Natrecor (nesiritide) for the treatment of patients with acutely decompensated congestive heart failure who have shortness of breath (dyspnea) at rest or with minimal activity. Natrecor is a new drug class, human B-type Natriuretic Peptides, made available as a therapeutic in the United States.
Serologicals Corporation Norcross, Georgia
Serologicals' antibody-based products are used as the active ingredients in therapeutic products for the treatment and management of diseases, such as Rh incompatibility in newborns, rabies and hepatitis and in diagnostic products such as blood typing reagents and diagnostic test kits. The Company also provides a variety of proteins used in the manufacturing of diagnostic reagents and genetically engineered biopharmaceuticals.
SICOR Inc. Irvine, California
SICOR Inc. is a vertically integrated, multinational pharmaceutical company that focuses on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients, or APIs, and generic biopharmaceuticals. Using internal research and development capabilities, together with operational flexibility and manufacturing and regulatory expertise, SICOR is able to take a wide variety of products from the laboratory to the worldwide market. Leveraging these capabilities, SICOR concentrates on products and technologies that present significant barriers to entry or offer first-to-market opportunities. SICOR operates several manufacturing facilities in the U.S., Western and Eastern Europe and Mexico, while maintaining its corporate headquarters in Irvine, California.
SkyePharma Inc. San Diego, California
SkyePharma PLC (located in London, UK) develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. Currently, there are nine approved products that incorporate three of SkyePharma's five technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilization capabilities. SkyePharma's US subsidiary, SkyePharma Inc. (formerly DepoTech Corporation) develops and manufactures injectable, sustained-release therapeutic products.
Sonus Pharmaceuticals, Inc. 22026 20th Avenue SE Bothell, Washington 98021
Sonus Pharmaceuticals, Inc. is focused on the development of novel drugs for the treatment of cancer that offer improved administration, tolerability, safety and effectiveness. The Company continues to advance the clinical and regulatory development of TOCOSOL Paclitaxel and is in the process of finalizing Phase 3 clinical testing plans for review by the U.S. Food and Drug Administration. With the promising clinical results to date, Sonus believes that TOCOSOL Paclitaxel may potentially offer a safer and more effective alternative paclitaxel therapy for cancer patients that is better tolerated and easier-to-use. In addition to executing the plans for TOCOSOL Paclitaxel, the Company remains focused on driving product and corporate development activities towards building and expanding its pipeline of oncology product candidates. Email: info@sonuspharma.com
Spectrum Pharmaceuticals, Inc. 157 Technology Drive Irvine, California 92618
Spectrum Pharmaceuticals is an oncology-focused pharmaceutical company engaged in the business of acquiring, developing and commercializing proprietary drug products which have a primary focus on the treatment of cancer and related disorders as well as generic drug products for various indications. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG, and has been granted fast-track status by the United States Food and Drug Administration (FDA). Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. EOquin(TM), a phase 2 drug, is being studied in the treatment of superficial bladder cancer. SPI-153 (formerly, D-63153), a phase 2 drug, is a 4th generation LHRH antagonist with the potential to treat hormone-dependent cancers as well as benign proliferative disorders, such as benign prostatic hypertrophy and endometriosis. In addition, the Company has two Abbreviated New Drug Applications for carboplatin and fluconazole, the generic equivalents of Paraplatin® and Diflucan®, respectively, under active review at the FDA. Email: info@spectrumpharm.com
STADA Pharmaceuticals USA, INC. 5 Cedar Brook Drive Cranbury, New Jersey 08512
STADA Pharmaceutical USA, INC. is a wholly owned subsidiary of STADA Arzneimittel AG. Headquartered in Cranbury, New Jersey is a leading pharmaceutical company specializing in the development and marketing of generic and branded pharmaceutical products for the U.S. Pharmaceutical market. The generic portfolio covers all major therapeutic areas with some emphasis on antibiotics. The product development strategy is supported by active development of new products, licensing and acquisitions. And, the company's foreseeable opportunities clearly exceed initial expectations by responsiveness to market needs. STADA outsources all of its manufacturing from world class contract manufacturers in the U.S. and Europe. This allows us to maintain the highest level of flexibility and market responsiveness, a true benefit for our customers. Distribution of our products has been outsourced as well, allowing for state of the art innovations in distribution that are aimed at optimizing service levels. STADA Pharmaceuticals, Inc. distributes its products through wholesalers, chain drug stores, retail pharmacies, mail order companies, managed Care organizations, hospital groups, nursing home providers and government agencies. Email: info@stadausa.com
SuperGen, Inc. Dublin, California
SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately, save the lives of those people afflicted with life-threatening diseases, especially cancer.
The company possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses.
The company is led by a seasoned management team with extensive experience in all aspects of the oncology pharmaceutical industry.
TabSafe Medical Services Alpharetta, Georgia
Prescription drug medications are timed released providing a medicine plan scheduled by a pharmacy in a locked medicine cabinet for senior citizens in assisted living and adult day care community housing centers to provide accurate and reliable prescription drugs and medication administration by TabSafe Medical Services, Inc. Email: cgillig@tabsafe.com
Taro Pharmaceuticals U.S.A., Inc. Hawthorne, New York
Taro markets a broad range of prescription and over-the-counter products in the United States. We are a leading manufacturer and supplier of topical dermatological products and also have a growing line of solid dosage form products used mainly in cardiology and neurology.
Teva Pharmaceuticals North America North Wales, Pennsylvania
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.
The Medicines Company 8 Campus Drive Parsippany, New Jersey 07054
The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve specialized care. The Company markets Angiomax® (bivalirudin), an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators.
The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 150 professionals.
In addition to the approved Angiomax product, The Medicines Company is developing clevidipine, a short-acting calcium channel blocker. The Medicines Company is also conducting significant clinical research to study potential additional indications for Angiomax use.
Titan Pharmaceuticals, Inc. South San Francisco, California
Titan Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system (CNS) disorders, cancer and other serious and life-threatening diseases. The company’s numerous products in development utilize innovative technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes important partnerships with multinational pharmaceutical companies and government institutions for the development of its products.
Transkaryotic Therapies Inc. (TKT) Cambridge, Massachusetts
TKT is a leading biotechnology company developing and commercializing
human proteins for a broad range of diseases, with a major focus on rare
genetic diseases. TKT currently markets one product, Replagal(TM) (agalsidase
alfa) for the treatment of Fabry Disease in the European Union and certain
other countries and has four products in clinical testing. TKT is
headquartered in Cambridge, Massachusetts and has a majority owned subsidiary
in Sweden, TKT Europe-5S AB, which is responsible for European sales and
marketing activities.
Triangle Pharmaceuticals, Inc. Durham, North Carolina
Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development of new antiviral drug candidates, with a particular focus on therapies for the human immunodeficiency virus (HIV) and the hepatitis B virus. Triangle's proprietary drug candidates under development for HIV and/or hepatitis B include Coviracil(R) (emtricitabine), amdoxovir (formerly DAPD) and clevudine (formerly L-FMAU).
Valeant Pharmaceuticals International One Enterprise Aliso Viejo, California 92656
Valeant Pharmaceuticals International (NYSE: VRX, effective November 14, 2003) is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products. (NOTE: Formerly known as ICN Pharmaceuticals) Email: info@valeant.com
Vela Pharmaceuticals Lawrenceville, New Jersey
Demand for medicines to treat psychiatric and neurological disorders is huge and growing. Worldwide spending for these therapies exceeded $46 billion in 2001. The Central Nervous System (CNS) medication market is the fastest growing of any major therapeutic area.
Vela Pharmaceuticals Inc. (VelaPharm) "rediscovers" and develops CNS medicines. By starting with molecules that have already been tested in humans, VelaPharm minimizes the risks of traditional drug discovery and development.
Partnering with VelaPharm is an attractive alternative for pharmaceutical companies with assets on the backburner. Taking full or partial ownership of such assets, the VelaPharm team puts it all into safe, efficient and fast development. The Company's ability to design and run optimal Phase II CNS programs is second to none. VelaPharm already has several promising assets in clinical development.
VelaPharm is led by experienced CNS pharmaceutical and CRO executives. VelaPharm's President and CEO is Kevin L. Keim, Ph.D., the former president of Quintiles' CNS Therapeutics group. He has recruited top performers from such organizations as Quintiles, Wyeth-Ayerst, Roche, Merck & Co., McKinsey & Company, and the National Institute of Mental Health.
Based in Lawrenceville, NJ, VelaPharm was incorporated in 1998. The company is backed by venture funding from JP Morgan Partners, New Enterprise Associates, Venrock, and others.
Email: info@velapharm.com
Vertex Pharmaceuticals Incorporated Cambridge, Massachusetts
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a global biotechnology company. Vertex seeks to discover, develop, and commercialize major pharmaceutical products independently and with partners. Chemogenomics, Vertex's proprietary, systematic, genomics-based platform, is designed to accelerate the discovery of new drugs and to expand intellectual property coverage of drug candidate compounds and classes of related compounds. This approach, which targets gene families, has formed the basis for several commercial collaborations under which Vertex retains rights to downstream revenue. Vertex's first approved product is Agenerase® (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with GlaxoSmithKline. Vertex has more than 12 drug candidates in clinical and preclinical development to treat viral diseases, inflammation, cancer, autoimmune diseases, neurological disorders and genetic disorders.
Vysis, Inc. Downers Grove, Illinois
Vysis, Inc., a wholly-owned subsidiary of Abbott Laboratories, is a leading Genomic Disease Management company that develops, commercializes and markets DNA-based clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis, originally Imagenetics Incorporated, was incorporated in 1991 as a division of Amoco Technology Company (a wholly-owned subsidiary of Amoco Corporation), and made its initial public offering of stock in 1998. The company was listed on the NASDAQ® stock exchange between 1998 and 2001. In October, 2001, Abbott Laboratories acquired Vysis as a wholly-owned subsidiary. The transaction was completed on December 5, 2001. Email: customerservice@vysis.com
Watson Pharmaceuticals, Inc. Corona, California
Watson Pharmaceuticals, Inc. has evolved into a specialty pharmaceutical company, focused on developing, manufacturing and marketing brand and generic pharmaceutical products utilizing various drug delivery technologies. These technologies include solid dosage form, oral controlled release, transdermal, oral transmucosal and drug cell targeting delivery systems.
Wyeth Madison, New Jersey
Wyeth (formerly American Home Products Corporation) is a research-based, global pharmaceutical company responsible for the discovery and development of some of today's most innovative medicines. Our products are sold in more than 140 countries, and our product portfolio includes innovative treatments across a wide range of therapeutic areas. Our worldwide resources include more than 52,000 employees, manufacturing facilities on five continents, and a discovery and development platform encompassing pharmaceuticals, vaccines and biotechnology.
Xenon Pharmaceuticals Inc. 3650 Gilmore Way Burnaby, BC, Canada V5G 4W8
Xenon Pharmaceuticals Inc. is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. Email: info@xenon-pharma.com
XOMA (US) LLC 2910 Seventh Street Berkeley, California 94710
XOMA develops and manufactures antibody and other protein-based biopharmaceuticals for disease targets that include immunological and inflammatory disorders, cancer and infectious diseases. XOMA's programs include collaborations: with Genentech, Inc. on the Raptiva(TM) antibody for psoriasis (BLA submission), psoriatic arthritis (Phase II) and other indications; and with Millennium Pharmaceuticals, Inc. on two biotherapeutic agents, CAB-2 and MLN2201, for vascular inflammation indications (preclinical and phase I, respectively). Earlier-stage development programs focus on antibodies and other compounds developed by XOMA for the treatment of cancer, retinopathies and acne. Email: InvestorRelations@xoma.com
Zengen, Inc. Woodland Hills, California
Incorporated in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengen's novel molecules were developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (alpha-MSH). A naturally occurring molecule, alpha-MSH modulates inflammatory and immune responses. James Lipton, Ph.D., Zengen's chief scientific officer, chairman of the scientific advisory board and director, and his collaborators first demonstrated that alpha-MSH possesses anti-inflammatory properties and uncovered the specific activity of the carboxy-terminal tripeptide region (C-terminal peptide) of the alpha-MSH peptide. These discoveries led to the development of Zengen's proprietary peptide molecules, including CZEN 002, a synthetic octapeptide. There is abundant evidence of the anti-inflammatory and anti-infective activity of these novel molecules from both in vivo and in vitro research. Zengen is currently conducting phase I/II clinical trials with CZEN 002 in vaginitis.
ZIOPHARM, Inc. 300 George Street New Haven, Connecticut 06511
ZIOPHARM, Inc. is a privately held company founded in January 2004 to develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer drugs. All products are focused on addressing unmet medical needs, with the potential for expedited approval and broad usage.
ZIOPHARM's first product, ZIO-101, is expected to enter Phase I human trials in 1Q 2005. The company anticipates licensing of ZIO-201 by 4Q 2004. ZIOPHARM is actively evaluating and negotiating for other product candidates and plans to in-license a third cancer therapy by 2Q 2005. Each product candidate undergoes a tightly managed evaluation process leveraging the company's management team's combined 100+ years of oncology experience in clinical development, regulatory strategy, business development and product commercialization. Email: info@ziopharm.com
ZymoGenetics, Inc. Seattle, Washington
ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for the prevention or treatment of significant human diseases. Using its proven product discovery engine, comprising genomics, bioinformatics, protein chemistry and preclinical biology, ZymoGenetics has generated a broad pipeline of proprietary product candidates. ZymoGenetics intends to commercialize these products through internal development, collaborations with biopharmaceutical partners, and out-licensing of its extensive patent portfolio.
Public
Feeds 
